J Electrochem Soc 1990,137(11):3612–3625.CrossRef 13. Torii A, Sasaki M, Hane K, Okuma S: A method for determining the spring constant of cantilevers for atomic force microscopy.

Meas Sci Technol 1996, 7:179–184.CrossRef 14. Bhushan B: Nano- to microscale wear and mechanical characterization using scanning probe microscopy. Wear 2001, 251:1105–1123.CrossRef 15. Johnson KL: Contact Mechanics. Cambridge, UK: Cambridge University Press; 1985.CrossRef 16. Vandeperre LJ, Giuliani F, Lloyd SJ, Clegg WJ: The hardness of silicon and this website germanium. Acta Mater 2007,55(18):6307–6315.CrossRef 17. Yu BJ, Li XY, Dong HS, Chen YF, Qian LM, Zhou ZR: Towards a deeper understanding of the formation of friction-induced hillocks on monocrystalline Olaparib ic50 silicon. J Phys D: Appl Phys 2012, 45:145301.CrossRef 18. Yu BJ, Qian LM, Dong HS, Yu JX, Zhou ZR: Friction-induced hillocks on monocrystalline silicon in atmosphere and in vacuum. Wear 2010, 268:1095–1102.CrossRef 19. Song CF, Li XY, Yu BJ, Dong HS, Qian LM, Zhou ZR: Friction-induced nanofabrication method to produce protrusive nanostructures on quartz. Nanoscale Res Lett 2011, 6:310.CrossRef

20. Guo J, Song CF, Li XY, Yu BJ, Dong HS, Qian LM, Zhou ZR: Fabrication mechanism of friction-induced selective etching on Si(100) surface. Nanoscale Res Lett 2012, 7:152.CrossRef 21. Stempflé P, Takadoum J: Multi-asperity nanotribological behavior of single-crystal silicon: crystallography-induced anisotropy in friction and wear. Tribol Int 2012, 48:35–43.CrossRef 22. Powell MJ, Wehrspohn RB, Deane SC: Nature of metastable and stable dangling bond defects

in hydrogenated amorphous silicon. J Non-Cryst Solids 2002, 299–302:556–560.CrossRef 23. Hesketh PJ, Ju C, Gowda S, Zanoria E, Danyluk S: Surface free energy model of silicon anisotropic etching. J Electrochem Soc 1993,140(4):1080–1085.CrossRef 24. Elwenspoek M: On the mechanism of anisotropic etching of silicon. J Electrochem Soc 1993,140(7):2075–2080.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions BY finished the fabrication experiments and acquired the original data in this article. LQ has made substantial contributions to conception and MRIP design for this article. Both authors read and approved the final manuscript.”
“Background With the growing interest in spin-based quantum computation and spintronic applications [1], there is an increasing need to understand and accurately determine critical parameters of the electron spin degree of freedom. It is well established that when measuring an electron spin in an external magnetic field B, it can either align parallel to or antiparallel to B. The energy difference between these two discrete states, also known as the spin gap or Zeeman splitting, is given by gμ B B where g is the Lande g-factor and μ B is the Bohr magneton.

cerevisiae. Tanespimycin research buy Mutat Res 2006, 593: 153–63.PubMed 6. de Padula M, Slezak G, Auffret van Der Kemp P, Boiteux S: The post-replication repair RAD18 and RAD6 genes are involved in the prevention of spontaneous mutations caused by 7,8-dihydro-8-oxoguanine

in Saccharomyces cerevisiae. Nucleic Acids Res 2004, 32: 5003–10.CrossRefPubMed 7. Notenboom V, Hibbert RG, van Rossum-Fikkert SE, Olsen JV, Mann M, Sixma TK: Functional characterization of Rad18 domains for Rad6, ubiquitin, DNA binding and PCNA modification. Nucleic Acids Res 2007, 35: 5819–30.CrossRefPubMed 8. Shiomi N, Mori M, Tsuji H, Imai T, Inoue H, Tateishi S, Yamaizumi M, Shiomi T: Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination. Nucleic

Acids Res 2007, 35: e9.CrossRefPubMed 9. Xin H, Lin W, Sumanasekera W, Zhang Y, Wu X, Wang Z: The human RAD18 gene product interacts with HHR6A and HHR6B. Nucleic Acids Res 2000, 28: 2847–54.CrossRefPubMed 10. Watanabe K, Tateishi S, Kawasuji M, Tsurimoto T, Inoue H, Yamaizumi M: Rad18 guides poleta to replication stalling sites through physical interaction and PCNA monoubiquitination. EMBO J 2004, 23: 3886–96.CrossRefPubMed 11. Sobin LH, Wittekind C: MS-275 datasheet UICC Tumor-Node-Metastasis Classification of Malignant Tumors. six edition. New-York: Wiley-Liss; 2002. 12. Shimizu S, Yatabe Y, Koshikawa T, Haruki N, Hatooka S, Shinoda M, Suyama M, Ogawa M, Hamajima N, Ueda R, Takahashi T, Mitsudomi T: High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res 2000, 6: 3994–9.PubMed 13. Ninomiya H, Nomura K, Satoh Y, Okumura S, Nakagawa K, Fujiwara M, Tsuchiya E, Ishikawa Y: Genetic instability in lung cancer: concurrent analysis of chromosomal, mini- and microsatellite instability and loss of heterozygosity. Br

J Cancer 2006, 94: 1485–91.CrossRefPubMed 14. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD: Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, GPX6 other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999, 5: 791–800.PubMed 15. Tai AL, Mak W, Ng PK, Chua DT, Ng MY, Fu L, Chu KK, Fang Y, Qiang Song Y, Chen M, Zhang M, Sham PC, Guan XY: High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers. Cancer Res 2006, 66: 4133–8.CrossRefPubMed 16. Economidou F, Tzortzaki EG, Schiza S, Antoniou KM, Neofytou E, Zervou M, Lambiri I, Siafakas NM: Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep 2007, 18: 1507–12.PubMed 17.

The association of PCDH8 methylation with the clinicopathological

PLX4032 nmr features is summarized in Table 2. The promoter methylation of PCDH8 in NMIBC tissues was correlated with, advanced stage (P = 0.0138), high grade (P = 0.0010), larger tumor size (P = 0.0482), tumor recurrence (P < 0.0001) and tumor progression (P < 0.0001) significantly. However, the promoter methylation of PCDH8 was not correlated with age, gender, and tumor number. Table 2 Relationship between PCDH8 methylation and clinicopathological characteristics in NMIBC (n = 233) Features Variables No. M (%) U (%) P Age 65 86 46(53.5) 40(46.5) 0.7342 >65 147 82(55.8) 65(44.2)   Sex Male 161 94(58.4) 67(41.6) 0.1135 Female 72 34(47.2) 38(52.8)   Number Single 142 82(57.8) 60(42.2) 0.2814 Multiple 91 46(50.6) 45(49.4)   Size ≤3 cm 139 69(49.6) 70(50.4) 0.0482 >3 cm 94 59(62.8) 35(37.2)   Grade G1/ G2 144 67(46.5) 77(53.5) 0.0010 G3 89 61(68.5)

28(31.5)   Stage Ta 95 43(45.3) 52(54.7) 0.0138 T1 138 85(61.6) 53(38.4)   Recurrence No 127 40(31.5) 87(68.5) <0.0001 Yes 106 88(83.0) 18(17.0)   Progression No 175 80(45.7) 95(54.3) <0.0001 Yes 58 48(82.8) 10(17.2)   M: Methylation; U: Unmethylation. The impact of PCDH8 methylation on the clinical outcome of NMIBC To examine if PCDH8 promoter methylation is a potential predictor of the prognosis in NMIBC, the recurrence-free survival, progression-free BGJ398 datasheet survival and five-year overall survival was analyzed, and the NMIBC patients was divided into two subgroup according to PCDH8 methylation status. Kaplan-Meier survival analysis and log-rank test suggested that NMIBC patients with PCDH8 methylated had significantly shorter recurrence-free survival (P < 0.0001; Figure 2), progression-free survival (P < 0.0001; Figure 3) and five-year overall survival (P = 0.0262; Figure 4) than patients with PCDH8 unmethylaed

Glutamate dehydrogenase respectively. Moreover, multivariate Cox proportional hazard model analysis indicated that PCDH8 promoter methylation in tissues was an independent predictor of shorter recurrence-free survival (P < 0.0001; Table 3), progression-free survival (P =0.0036; Table 4) and five-year overall survival (P = 0.0015; Table 5). Figure 2 Correlations between PCDH8 methylation and recurrence-free survival in NMIBC patients. Patients with PCDH8 methylated showed significantly shorter recurrence-free survival than patients without (P < 0.0001, log-rank test). Figure 3 Correlations between PCDH8 methylation and progression-free survival in NMIBC patients. Patients with PCDH8 methylated showed significantly shorter progression-free survival than patients without (P < 0.0001, log-rank test). Figure 4 Correlations between PCDH8 methylation and five-year overall survival in NMIBC patients. Patients with PCDH8 methylated showed significantly shorter five-year overall survival than patients without (P = 0.0177, log-rank test).

S. suis strain 10 highly tolerated 100-fold MIC of gentamicin, whereas the other streptococcal strains were completely killed after one hour. These data suggest that a specific mechanism for

gentamicin tolerance of S. suis persisters may have evolved and that this is, most likely, not due to a shared genetic background within the genus Streptococcus. Interestingly, after gentamicin treatment of S. suis we also observed a small-colony-variant (SCV) like phenotype (data not shown) that has also been reported for S. aureus upon aminoglycoside treatment [15, 48]. Although it reverted to the typical large-colony phenotype after subcultivation, it remains to be elucidated if this phenotype will change to a stable phenotype after longer exposure times and altered antibiotic tolerance to aminoglycosides. However, at the stationary growth phase the investigated S. suis GSK 3 inhibitor strain 10 highly tolerated several antimicrobials targeting

different bacterial components over time. Given the high selleck chemicals llc rate of multi-drug tolerant cells produced by S. suis strain 10 during stationary growth, it was remarkable that the cyclic lipopeptide daptomycin efficiently eradicated this subpopulation. This is in contrast to observations that in S. aureus 100-fold MIC of daptomycin failed to eradicate stationary phase cultures [15]. Even though the MIC for daptomycin is rather high when compared to that of other streptococcal species [49] this treatment eradicated S. suis persister cells in vitro. In the last years bacterial persistence and enhanced antibiotic tolerance was intensively discussed in the context of recurrent infections caused by bacterial pathogens. Interestingly, a human case of recurrent septic shock due to a S. suis serotype 2 infection has previously been reported [50]. Together with our present

study this suggests next a clinical relevance of S. suis persisters. Although experimental evidence for S. suis persister cell and biofilm formation in vivo is yet missing, S. suis is able to produce biofilms in vitro that tolerate antibiotic challenge [51, 52]. Given the fact that the S. suis colonization rate of pigs is nearly 100% [35, 53, 54] and that antibiotic treatment with penicillin, ampicillin, or ceftiofur failed to eliminate the tonsillar carrier state of S. suis in swine [55], it is plausible to speculate that persister cells, possibly also as part of biofilm structures, may contribute to the observed problems in antibiotic treatments. Indeed, P. aeruginosa persister cells have been described as the dominant population responsible for drug tolerance in biofilms [22]. Conclusions Our study showed that the zoonotic pathogen S. suis is able to form a multi-drug tolerant persister cell subpopulation. S. suis persister cells tolerated a variety of antimicrobial compounds that were applied at 100-fold of MIC and could be detected in different S. suis strains.

Analysis of the corresponding patient information of eight isolates revealed two patients

exhibiting colonic malignancies, three patients with intestinal abnormalities and three patients without evidence of intestinal abnormalities (Table 1). For the other eleven human clinical isolates, patient data was not available because isolates were obtained from other institutes and repeatedly characterized in our microbiological https://www.selleckchem.com/products/Trichostatin-A.html laboratory. Adhesion to and invasion of EA.hy926 cells All strains started to grow after 3 h of incubation in DMEM at 37°C and 5% CO2 at the earliest (data not shown). Therefore, incubation time for adhesion was determined to 2 h to avoid false-high titers as a result of bacterial growth kinetics. Three strains

representing different adherence and invasion potentials, namely strain DSM 16831 (low adhesion, no invasion), isolate 21702 (intermediate adhesion and invasion) and isolate 05950 (high adhesion and invasion), were chosen to exemplify the dose-dependent effects on adhesion and invasion to EA.hy926 cells (Fig. 1). The proportion of adhesive and invasive bacteria did not increase using higher bacterial concentrations, with both, the adhesiveness and the invasiveness of the different bacteria showing a linear progress. Remarkably, strain DSM 16831 did not have the potential www.selleckchem.com/products/Vincristine-Sulfate.html to invade cells, even when higher bacterial concentrations were used for infection. Subsequently, all S. gallolyticus strains were compared regarding their adhesion and invasion characteristics to EA.hy926 cells (Fig. 2). As a result of the observed linear progress and for strain comparability the initial inocula were calculated to 1 × 105 CFU/mL, and consequently adhesion and invasion values were factorized. Generally, all the S. gallolyticus strains analyzed were able to adhere to EA.hy926 endothelial

cells (range 103-104 recovered CFU/mL) and significant differences were observed among the investigated strains (repeated measures anova, P < 0.0001). Consideration of the individual strains revealed that isolates 13366, K6236 and AC1016 presented the most frequently significances (Fig. 2). With the exception of strain DSM 16831, which was excluded in further statistical analysis regarding invasion characteristics, Thalidomide all S. gallolyticus strains also had the capacity to invade EA.hy926 cells (range 101 – 103 recovered CFU/mL) with significant differences (repeated measures anova, P < 0.0001). A closer look on variation between individual strains disclosed, that the potential of invasion of the two strains DSM 13808 and isolate 05950 demonstrated numerous significances overall (DSM 13808: 17 strains, P < 0.001; isolate 05950: five strains, P < 0.001 and seven strains P < 0.01, Fig. 2). Correlation analysis of adherence and invasion showed a strong correlation for all strains (Spearman rank correlation coefficient r = 0.673, P = 0.0003).

More than two-thirds of patients with advanced cancer have pain [1]. Controlling pain and managing symptoms are important goals of cancer treatment [2]. Flurbiprofen is a non-selective cyclooxygenase inhibitor used in clinic as nonsteroidal anti-inflammatory

drug [3]. Flurbiprofen axetil, an injectable prodrug of flurbiprofen [4], has been reported to be associated with a reduction postoperative pain [5, 6], propofol injection pain [7, 8], and in initial treated pain induced from cancer [9]. The role of flurbiprofen axetil are not yet clear in the routinely administration of refractory cancer pain. In the present study, we reported the role of intravenous flurbiprofen axetil in this area. Methods Patients Cancer pain cases whose pain had not been treated satisfactorily this website with routine narcotics

were selected from the department of medical oncology, the first affiliated hospital of Anhui medical university in China between October of 2007 and October of 2008. Each cancer case was diagnosed and confirmed Selleckchem Rapamycin by histopathology or cytopathology. Clinical data and follow-up information were obtained from the hospital records. The study protocol was approved by the local institutional ethics committee, and verbal informed consent was obtained from each patient. Patients with difficulty communicating, a history of adverse response to flubiprofen axetil, or who felt no pain after received other analgesic drugs within 24 hours were excluded. Dosage and usage of flurbiprofen axetil injection All selected patients were received Myosin 50 mg/5 ml/day of intravenous flurbiprofen axetil injection (50 mg/5 ml, Beijing Tide Pharmaceutical. Co., Ltd, Beijing, China), as flurbiprofen axetil 50 mg added in 100 ml of 0.9% isotonic saline

every time through vein within 30 minutes. Dosage and usage of the anaesthetic drugs such as Oxycodone, Tramadol, Duragesic and adjuvant drugs such as diazepam, carbamazepine which being used initially were not changed, or be reduced and ceased after the pain was relieved completely. Other accompanying adjuvant treatments also had been included chemotherapy, radiotherapy, best sustain therapy, bisphosphonate therapy, and etc. Evaluating criteria We evaluated cancer pain intensity by Pain Faces Scale criteria [10], and the three grades as: Mild pain (1–3): Cancer pain could be endurable, and sleep was effected slightly, action was freely, no pain was in the patient’s face; Moderate pain (4–6): Cancer pain could be endurable yet, and sleep was effected obviously, action was limited, pain was showed in the patient’s face; Severe pain (7–10): Cancer pain could not be endurable, and sleep was effected severely, action was limited hardly, more pain was showed in the patient’s face, body’s style was passively.

: Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scandinavian journal of gastroenterology 2005,40(3):286–296.CrossRefPubMed 24. Xue ML, Thakur A, Lutze-Mann L, Willcox MD: Pro-inflammatory cytokine/chemokine gene expression in human corneal epithelial cells colonized by SRT1720 molecular weight Pseudomonas aeruginosa. Clinical & experimental ophthalmology 2000,28(3):197–200.CrossRef 25. Lindhe J, Ranney RR, Lamster IB, Charles A,

Chung CH, Flemmig TF, Kinane DF, Listgarten MA, Löe H, Schoor R, et al.: Consensus report: Periodontitis as a manifestation of systemic diseases. Ann Periodontol 1999,4(1):64.CrossRef 26. Socransky SS, Smith C, Martin L, Paster BJ, Dewhirst FE, Levin AE: “”Checkerboard”" DNA-DNA hybridization.

Biotechniques 1994,17(4):788–792.PubMed 27. Papapanou PN, Neiderud A-M, Papadimitriou A, Sandros J, Dahlén G: “”Checkerboard”" assessments of periodontal microbiota and serum antibody responses: A case-control study. J Periodontol 2000,71(6):885–897.CrossRefPubMed 28. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide MLN2238 mouse array probe level data. Biostatistics (Oxford, England) 2003,4(2):249–264. 29. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Sacco RL, Papapanou PN: Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular

Disease Epidemiology Study (INVEST). Circulation 2005,111(5):576–582.CrossRefPubMed 30. World Workshop in Periodontics: Consensus report periodontal diseases: Pathogenesis and microbial factors. Annals of Periodontol 1996,1(1):926–932.CrossRef 31. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr: Microbial complexes in subgingival plaque. J Clin Periodontol 1998,25(2):134–144.CrossRefPubMed 32. Storey JD, Tibshirani R: Statistical significance Grape seed extract for genomewide studies. Proc Natl Acad Sci USA 2003,100(16):9440–9445.CrossRefPubMed 33. Lee HK, Braynen W, Keshav K, Pavlidis P: ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 2005, 6:269.CrossRefPubMed 34. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al.: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001,29(4):365–371.CrossRefPubMed 35. Kebschull M, Demmer R, Behle JH, Pollreisz A, Heidemann J, Belusko PB, Celenti R, Pavlidis P, Papapanou PN: Granulocyte chemotactic protein 2 (GCP-2/CXCL6) complements interleukin-8 in periodontal disease. J Periodontal Res 2009,44(4):465–471.CrossRefPubMed 36. Paster BJ, Olsen I, Aas JA, Dewhirst FE: The breadth of bacterial diversity in the human periodontal pocket and other oral sites. Periodontol 2000 2006, 42:80–87.CrossRefPubMed 37.

The Integrin family of cell adhesion receptors has been implicated in tumour progression as they contribute to the interplay between tumour and micro-environment by binding directly to components of the extracellular matrix (ECM) [24]. Due to the abundance of ECM, the integrin-mediated cell adhesion signalling may play an important role in PDAC tumour growth, migration and even in therapy resistance [25, 26]. Various integrins, such as ITGA6, ITGB4 and ITGB5, are upregulated in ‘Good’ and/or ‘Bad’ PDAC samples. In cell culture studies, ITGB1 has been shown to play a critical role in pancreatic cancer progression and in metastasis in particular [27, 28]. Upregulation of ITGB1

CDK inhibitor review in ‘Bad’ PDAC, might highlight its potential therapeutical impact. Ephrin receptors are similarly promising therapeutical targets as they mediate cell-cell interactions both in tumour cells and in the tumour micro-environment, and thereby may affect tumour growth, invasiveness, angiogenesis, and metastasis [29]. EPHA2, related to poor

clinical outcome in PDAC, has already been successfully investigated as target in PDAC cell lines [30, 31]. Indeed, in our study, EPHA2 was highly upregulated as PDAC with poor outcome, supporting its potential clinical relevance. Embryonic signalling pathways are known to play a role in both the tumoural and the stromal compartment and in different stages of PDAC [32]. Hedgehog signalling (Shh) e.g. has been implicated in the initiation learn more of PDAC, and was overexpressed in PDAC samples with good overall survival in our series [33, 34]. The Wnt/β-catenin pathway seems to be involved in a later stage of PDAC tumorigenesis [9, 34, 35]. In our study, elements from the canonical Wnt/β-catenin pathway were upregulated in all PDAC samples. However, in patients with poor survival, genes

from both the canonical and non-canonical pathway, including Wnt5A and DVL1, were upregulated [35, 36]. The expression of Wnt5A has already been shown to be induced in PSC [35]. Upregulation of DKK1, a Wnt/β-catenin pathway antagonist, may promote tumour invasiveness though the exact mechanism is yet unknown [37]. Overexpression of Notch signalling in PDAC correlates with tumour proliferation and migration [38]. Notch has been shown to Unoprostone regulate pancreatic cancer stem cells and would have a role in the acquisition of epithelial-mesenchymal transition (EMT) by inducing SNAI2 expression due to JAG1 overexpression [39, 40]. Although JAG1 was upregulated in all our PDAC samples irrespective of survival, SNAI2 was upregulated in the ‘Bad’ versus ‘Good’ PDAC samples. The upregulation of many EMT-related genes, such as TGFβR1, FGFBP1 TGFβ1 LOXL2, TWIST1 and Wnt5A, and the downregulation of FOXA1 in the ‘Bad’ PDAC samples might support the role of EMT in the aggressiveness of PDAC [41].

Atoms are colored according to their height in Y direction. (e,f,g,h) Cross-sectional views of the substrate after scratching with probe radiuses of 6, 8, 10, and 12 nm, respectively. Atoms are colored according to shear strain ranging from 0 selleck chemical to 1. Figure 7 presents numbers of HCP and defect atoms generated within the substrate after penetration and scratching with the four probe radiuses. For each probe, there are more HCP and defect atoms generated in the scratching stage than that in penetration stage, because of the more complex plastic deformation associated with the multi-axial localized stress states. When the probe radius is not larger than 10 nm, there are more defect

atoms than HCP atoms in both penetration and scratching stages for each probe radius. However, the friction with the probe radius of 12 nm results in

more HCP atoms than defect atoms generated within the material. The formation of HCP atoms is associated with the activity of partial dislocations, while defect atoms are composed of not only dislocation https://www.selleckchem.com/products/cx-4945-silmitasertib.html cores but also vacancies. Therefore, Figure 7 indicates that the dislocation activity plays more pronounced role in governing incipient plasticity for larger probe. In addition, the incipient plasticity shows strong dependence on probe radius: the larger the probe, the larger both the HCP and defect atoms. Figure 7 Influence of probe radius Rucaparib order on numbers of HCP and defect atoms generated within the substrate under friction. Conclusions In summary, we perform MD simulations to investigate the atomic scale origin of the minimum wear depth of single crystalline Cu(111) during single asperity friction. Simulation results show that scratching impression can only be made under a scratching depth at which there are permanent defects formed. It is indicated that the minimum wear depth is equivalent to the critical penetration depth associated with the first force-drop observed

in the force-depth curve. The specific permanent defects governing the wear phenomena are composed of stair-rod dislocations and prismatic dislocation loops as well as vacancies. While the contact pressure for the nucleation of initial dislocation is independent on probe radius, the minimum wear depth increases with probe radius. Further analysis of the shear strain distribution implies that a larger probe results in more compliant deformation of the material, which leads to larger volume of wear debris and wider extent of defect structures. Acknowledgements The authors greatly acknowledge financial supports from the NSFC (51005059 and 51222504), China Postdoctoral Science Foundation (20100471047 and 2012 M511463), and Heilongjiang Postdoctoral Foundation of China (LBH-Z11143). JZ also greatly acknowledges Dr. Alexander Hartmaier and Dr.

Comparing H- and O- PSi, we note that the upper singlet lifetimes and the excitonic energy splitting of both H-PSi and O-PSi remarkably coincide over the entire range of measured photon energies (see Figure 4a,b), while

the lower triplet lifetime of H-PSi is shorter than that of O-PSi over the same range of energies (Figure 4c). This result is the basis for our conclusion (to be discussed hereafter) that oxidation of (freshly prepared) H-PSi gives rise to slower nonradiative lifetimes, leaving radiative selleck compound lifetimes unaffected. Figure 4 Triplet and singlet lifetimes and energy splitting. (a) the upper singlet lifetime; (b) the excitonic energy splitting; (c) the lower triplet lifetime (extracted from

PD98059 mw the fit to the singlet-triplet model; see Figure 3) as a function of the photon energy. Discussion As explained above, the main finding of this work is that the oxidation of freshly prepared luminescent PSi gives rise to slower triplet lifetimes, keeping the upper singlet lifetimes unaffected. Before discussing the implications of this result, let us denote that the measured decay rate is the sum of two competing relaxation processes given by (3) where τ R -1 is the radiative transition rate (given by Equation 2), τ NR -1 is the nonradiative relaxation rate, and τ -1 is the total decay rate. The integrated PL (i.e., the area below the PL spectrum shown at the inset to Figure 1) is proportional to the quantum

yield that is given by the ratio of the radiative to the total decay rate, . The variation of the integrated PL with temperature is shown in Figure 3b on a semi-logarithmic scale, similar to that of Figure 3a for the PL lifetime. Notice that while the PL lifetime varies by approximately two orders of magnitude over the 30 to 300 K temperature range, the integrated PL varies by less than 3. Hence, one concludes that at this temperature range, τ R < < τ NR, leading to, τ ≈ τ R (Equation 3), and η ≈ constant Lck (as in reference [37]). Thus, at temperatures above 30 to 40 K the measured lifetime is dominated by radiative transitions. In addition, the strong dependence of the upper singlet lifetime on photon energy (a decrease from 6 to 7 μs at 1.6 eV down to 200 to 300 ns at 2.3 eV; see Figure 4a), suggests again that this lifetime should be associated with radiative transitions (where τ U ~ τ R U < < τ NR U). In this case, the fast radiative lifetime is due to the influence of confinement on the spontaneous emission rates in small Si nanocrystals [39, 40]. On the other hand, the lower triplet lifetime that is dominant at low temperatures is approximately constant (varies by less than factor of 2 over the same range of energies) and roughly independent of the photon energy that probes a given size of nanocrystals.